Ironwood Pharmaceuticals, Inc. (IRWD)
3.46
-0.11
(-3.08%)
USD |
NASDAQ |
Oct 23, 16:00
3.455
0.00 (0.00%)
Pre-Market: 20:00
Ironwood Pharmaceuticals Enterprise Value : 889.47M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 889.47M |
| October 22, 2026 | 907.65M |
| October 21, 2026 | 904.34M |
| October 20, 2026 | 917.56M |
| October 19, 2026 | 905.99M |
| October 16, 2026 | 896.08M |
| October 15, 2026 | 940.69M |
| October 14, 2026 | 912.60M |
| October 13, 2026 | 910.95M |
| October 12, 2026 | 939.04M |
| October 09, 2026 | 948.96M |
| October 08, 2026 | 957.22M |
| October 07, 2026 | 937.39M |
| October 06, 2026 | 917.56M |
| October 05, 2026 | 920.86M |
| October 02, 2026 | 919.21M |
| October 01, 2026 | 939.04M |
| September 30, 2026 | 973.74M |
| September 29, 2026 | 1.005B |
| September 28, 2026 | 998.53M |
| September 25, 2026 | 1.000B |
| September 24, 2026 | 1.010B |
| September 23, 2026 | 1.023B |
| September 22, 2026 | 1.065B |
| September 21, 2026 | 1.046B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.038B |
| September 17, 2026 | 1.017B |
| September 16, 2026 | 1.007B |
| September 15, 2026 | 988.61M |
| September 14, 2026 | 1.007B |
| September 11, 2026 | 991.92M |
| September 10, 2026 | 973.74M |
| September 09, 2026 | 990.27M |
| September 08, 2026 | 1.007B |
| September 04, 2026 | 1.022B |
| September 03, 2026 | 1.027B |
| September 02, 2026 | 1.046B |
| September 01, 2026 | 1.023B |
| August 31, 2026 | 1.020B |
| August 28, 2026 | 1.000B |
| August 27, 2026 | 1.018B |
| August 26, 2026 | 1.027B |
| August 25, 2026 | 1.043B |
| August 24, 2026 | 1.000B |
| August 21, 2026 | 1.027B |
| August 20, 2026 | 1.002B |
| August 19, 2026 | 1.038B |
| August 18, 2026 | 1.030B |
| August 17, 2026 | 1.038B |
| August 14, 2026 | 1.030B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 569.05B |
| Xencor, Inc. | 1.585B |
| Viking Therapeutics, Inc. | 2.349B |
| IDEAYA Biosciences, Inc. | 2.546B |
| BioMarin Pharmaceutical, Inc. | 14.17B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 51.29M |
| Revenue (Quarterly) | 113.04M |
| Total Expenses (Quarterly) | 61.75M |
| EPS Diluted (Quarterly) | 0.3068 |
| Gross Profit Margin (Quarterly) | 99.60% |
| Profit Margin (Quarterly) | 45.37% |
| Earnings Yield | 22.16% |
| Operating Earnings Yield | 40.49% |
| Normalized Earnings Yield | 22.38 |